Automating Allergy & Immunology GLP-1 Prior Auth Workflows

Managing the increasing volume of allergy & immunology GLP-1 prior auth requests requires specialized automation. Klivira integrates directly into your EMR to streamline this complex workflow.

Allergy and immunology practices frequently manage high-cost biologics and immunotherapies, which already demand significant prior authorization resources. The recent surge in GLP-1 receptor agonist prescriptions, including Ozempic, Wegovy, Mounjaro, and Zepbound, adds another layer of complexity, often requiring detailed documentation for indications ranging from Type 2 Diabetes to obesity management. This creates a substantial administrative burden for prior authorization coordinators and revenue cycle teams.

The Unique Challenges of GLP-1 PAs in Allergy & Immunology

While allergy & immunology practices are accustomed to navigating prior authorizations for high-cost medications like asthma biologics or IVIG, GLP-1 PAs introduce distinct requirements. These often involve meticulous documentation of BMI, A1C levels, and prior step therapy, alongside navigating variable payer coverage for obesity indications. This adds to an already high-volume PA environment for conditions such as asthma biologics, IVIG/SCIG, and allergen immunotherapy.

Common Triggers and Data Points for GLP-1 Prior Auth

**Indication Classification:** Differentiating between Type 2 Diabetes and obesity indications for drugs like Ozempic, Wegovy, Mounjaro, Zepbound, and Saxenda.
**Step Therapy Requirements:** Documenting trials of preferred agents, such as metformin, often pulled directly from EMR medication histories.
**Clinical Criteria:** Capturing specific patient data points including BMI, A1C, and comorbidity status, which are critical for meeting payer guidelines.
**Payer-Specific Obesity Coverage:** Identifying whether a patient's plan covers anti-obesity medications, as coverage varies widely.
**Brand-Specific Criteria:** Applying distinct PA logic for different GLP-1 products, each with unique approval pathways.

Klivira's Automated Approach to GLP-1 Prior Auth

Klivira's platform is engineered to manage the specific demands of GLP-1 prior authorizations within an allergy & immunology context. Our system integrates with your EMR to automate data extraction, apply payer-specific rules, and streamline submission, significantly reducing manual effort and improving turnaround times. We leverage industry standards like FHIR for seamless data exchange and support various ePA channels including X12 278 and payer portals.

Key Automation Features for Allergy & Immunology GLP-1 PAs

**Indication-Aware Routing:** Automatically classifies T2D versus obesity indications based on EMR diagnosis and clinical context.
**Dynamic Policy Engine:** Maintains up-to-date per-payer obesity benefit status and routes submissions accordingly, minimizing denials.
**Automated Step Therapy Documentation:** Extracts metformin trial history, BMI, and comorbidity status directly from FHIR-enabled EMRs.
**Brand-Specific Logic:** Applies unique prior authorization criteria for specific GLP-1 products (e.g., Ozempic, Wegovy, Mounjaro, Zepbound).
**Integrated Specialty Pharmacy Fulfillment:** Facilitates post-approval routing to specialty pharmacies for many GLP-1 medications.
**Patient Financial Counseling:** Surfaces manufacturer copay programs and alternative coverage paths when obesity indications are denied.

Leveraging Clinical Guidelines and EMR Integration

Our automation workflows are informed by established clinical guidelines, such as the ADA Standards of Care for Type 2 Diabetes treatment algorithms, ensuring that submitted documentation aligns with evidence-based criteria. Klivira's SMART on FHIR integration allows for direct access to critical patient data within your EMR, including diagnosis codes, lab results (A1C), and vital signs (for BMI calculation), reducing the need for manual chart review and data entry.

Frequently asked questions

How does Klivira handle the distinction between T2D and obesity indications for GLP-1s?

Klivira's system automatically identifies the indication (Type 2 Diabetes vs. obesity) from EMR diagnosis codes and clinical context. It then applies the appropriate payer-specific criteria and documentation requirements, ensuring accurate submission for drugs like Ozempic, Wegovy, Mounjaro, and Zepbound.

What EMR data points are critical for automating GLP-1 prior authorizations in an A&I practice?

Key data points include diagnosis codes (e.g., for T2D or obesity), A1C levels, BMI (calculated from height and weight), and documentation of previous medication trials like metformin. Klivira leverages SMART on FHIR to pull these essential data elements directly from your EMR.

How does Klivira manage varying payer coverage for obesity-related GLP-1 prescriptions?

Our policy engine maintains an up-to-date library of per-payer obesity benefit statuses (covered, restricted, not-covered). Klivira automatically routes the prior authorization based on this information, providing transparency and potentially surfacing patient financial counseling options if coverage is denied.

Can Klivira automate step therapy documentation for GLP-1s?

Yes, Klivira automates the documentation of step therapy by extracting relevant medication history, such as metformin trial details, directly from your EMR via FHIR. This ensures that all required prior treatment failures or contraindications are accurately presented to the payer.

Does Klivira integrate with specialty pharmacies for GLP-1 fulfillment?

For many GLP-1 products, particularly those requiring specialty pharmacy dispensing, Klivira facilitates post-approval routing. This streamlines the transition from prior authorization approval to medication fulfillment, ensuring patients receive their prescriptions efficiently.